Sugi Predict

Sugi Predict / Compounds / SCHEMBL7325345

SCHEMBL7325345

SCHEMBL7325345

CCCCNC(=O)CC(C)C

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.59
▸ TP53 P04637 1/20 0.59
▸ KMT2A Q03164 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ CASP2 P42575 1/20 0.50
▸ EPHX1 P07099 6/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ NAAA Q02083 1/20 0.47
▸ ACHE P22303 1/20 0.45
▸ MMP2 P08253 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ FAAH O00519 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ CNR1 P21554 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7035049 0.94 CASP2 (0.59) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL25616595 0.92 SMN1; SMN2 (0.53) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL15855111 0.92 CASP2 (0.62) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL15855095 0.92 CASP2 (0.62) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL15855158 0.92 CASP2 (0.62) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL24047859 0.92 CASP2 (0.62) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL18199495 0.89 SMN1; SMN2 (0.66) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL20340484 0.89 SMN1; SMN2 (0.66) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL25791316 0.87 CASP2 (0.61) SMN1; SMN2TP53KMT2AHPGDALDH1A1
SCHEMBL1577892 0.86 SMN1; SMN2 (0.53) SMN1; SMN2TP53KMT2AHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230146870-A1 METHOD TO QUANTIFY AFFINITY AND SELECTIVITY OF SMALL MOLECULES FOR PROTEINS IN LIVING CELLS OHIO STATE INNOVATION FOUNDATION 2023-05-11 — — US disclosed
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-01-19 — — US disclosed
US-11357865-B2 Compositions containing nucleic acid nanoparticles with modular functionality Sixfold Bioscience Ltd. (GB) 2022-06-14 — — US disclosed
US-20210405060-A1 METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES Revolution Medicines, Inc. 2021-12-30 — — US disclosed
US-20210330810-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY Sixfold Bioscience Ltd. (GB) 2021-10-28 — — US disclosed
US-20210285955-A1 METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES WARP DRIVE BIO, INC. 2021-09-16 — — US disclosed
WO-2021127460-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2021-06-24 — — WO disclosed
EP-3452172-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS Yale University (US) 2019-03-13 — — EP disclosed
US-9938234-B2 PPAR agonists SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2018-04-10 — — US disclosed
WO-2017192799-A1 COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS YALE UNIVERSITY (US) 2017-11-09 — — WO disclosed
US-20140346397-A1 COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES ALEXION PHARMA INTERNATIONAL OPERATIONS UNLIMITED COMPANY (IE) 2014-11-27 — — US disclosed
US-20140186923-A1 COMPOUNDS AND METHODS FOR PURIFICATION OF SERINE PROTEASES PORTOLA PHARMACEUTICALS, INC. (US) 2014-07-03 — — US disclosed
US-5827863-A Pyrazole derivatives as angiotensin II antagonists J. URIACH & CIA, S.A. (ES) 1998-10-27 — — US disclosed
US-5614519-A (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists KARL THOMAE GMBH (DE) 1997-03-25 — — US disclosed
US-5602127-A ADMINISTERING TO TREAT HYPERTENSION KARL THOMAE GMBH (DE) 1997-02-11 — — US disclosed
US-5594003-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-14 — — US disclosed
US-5591762-A HYPOTENSIVE AGENTS DR. KARL THOMAE GMBH (DE) 1997-01-07 — — US disclosed
WO-1996004273-A1 NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST J. URIACH & CIA, S.A. (ES) 1996-02-15 — — WO disclosed
EP-0369743-B1 Heterocyclic amides ZENECA LTD (GB) 1995-04-19 — — EP disclosed
EP-0369743-A2 Heterocyclic amides ZENECA LIMITED (GB) 1990-05-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11357865-B2 Compositions containing nucleic acid nanoparticles with modular functionality NCL, NSUN3, POLN SMN1; SMN2 657/4885TP53 218/4885KMT2A 2142/4885
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, NPC1L1 SMN1; SMN2 2619/4885TP53 4090/4885KMT2A 4362/4885
US-20210330810-A1 COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY NCL, NSUN3, POLN SMN1; SMN2 657/4885TP53 218/4885KMT2A 2142/4885
US-20210405060-A1 METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES FKBP8, PIN1, FKBP1A SMN1; SMN2 4204/4885TP53 646/4885KMT2A 4359/4885
US-20210285955-A1 METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES FKBP8, PIN1, FKBP1A SMN1; SMN2 4204/4885TP53 646/4885KMT2A 4359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.